Received Feb 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 47XP4 | — |
Adult patient received Engerix B pediatric; Adult patient received Engerix B pediatric; This non-serious case was reported by a other health professional via patient support programs and described the occurrence of underdose in a 37-year-old male patient who received HBV (Engerix B pediatric) (batch number 47XP4, expiry date 16-JUL-2026) for prophylaxis. On 19-FEB-2025, the patient received Engerix B pediatric .5 ml. On 19-FEB-2025, an unknown time after receiving Engerix B pediatric, the patient experienced underdose (Verbatim: Adult patient received Engerix B pediatric) and adult use of a child product (Verbatim: Adult patient received Engerix B pediatric). The outcome of the underdose and adult use of a child product were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 19-FEB-2025 The patient weight reported 67.59 kilogram. Adult patient received Engerix B pediatric, which led to an underdose and adult use of a child product.